Study to Evaluate the Effect of a Nu Skin Product and Device for Brown Spots
NCT ID: NCT01149876
Last Updated: 2014-11-06
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
80 participants
INTERVENTIONAL
2010-06-30
2011-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Evaluation of the Tolerance (Main Objective) and Performance of Cyto-selective Difluoroethane-based Cryotherapy in the Treatment of Brown Spots (Solar and Senile Lentigines, Post-inflammatory Hyperpigmentation) on the Face
NCT06305897
The Smartlipo Triplex 1440nm Wavelength Laser and the Sidelaze 800 Hand Piece for the Treatment of Facial Acne Scars
NCT02103816
Trial Comparing Treatment of Tretinoin or Superficial Dermabrasion for Stretch Marks
NCT01027793
Evaluation of the Efficacy and Tolerance of a Light Therapy Mask on Mild to Moderate Brown Spots and Moderate to Severe Facial Wrinkles
NCT03312543
Clinical Study for the Efficacy Evaluation of a Food Supplement
NCT06453837
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Nu Skin Product
Nu Skin Product
Thin layer of Nu Skin product applied to face.
Nu Skin product with galvanic spa system
Nu Skin Product
Thin layer of Nu Skin product applied to face.
Cosmetic instrument
Cosmetic instrument with topical Nu Skin product. Thin layer of Nu Skin product applied to face followed by galvanic, used for 3 minutes.
Tretinoin cream 0.05
Tretinoin cream 0.05
Thin layer of tretinoin applied to face.
over the counter moisturizer
CeraVe moisturizer
Thin layer of CeraVe applied to face.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Nu Skin Product
Thin layer of Nu Skin product applied to face.
Cosmetic instrument
Cosmetic instrument with topical Nu Skin product. Thin layer of Nu Skin product applied to face followed by galvanic, used for 3 minutes.
Tretinoin cream 0.05
Thin layer of tretinoin applied to face.
CeraVe moisturizer
Thin layer of CeraVe applied to face.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Able to complete study and comply with study procedures.
* Caucasian female ages 25-55.
* Presence of photodamage and lentigines of II-III on the Glogau Photoaging
* Must be willing to avoid laser and light treatments, treatments with filler, chemical peels, microdermabrasion, Botox or any other cosmetic treatment to the face during the duration of the study.
* Must be willing to avoid changing topical moisturizers and cosmetics during the study.
* Able to stop any alpha or beta hydroxy acids, topical retinol or retinoid derivatives, topical antioxidants, or any topical product that may interfere with the study 2 weeks prior to the study.
Exclusion Criteria
* Current smoker.
* Pregnant, nursing, or planning to become pregnant during study.
* Currently taking drugs including oral retinoids or any other medication with a known clinically significant drug interaction with topical tretinoin.
* Known hypersensitivity to retinoids. History of severe retinoid dermatitis.
* History of substance abuse, mental dysfunction, or other factors limiting ability to cooperate with study.
* Concurrent participation in another clinical study or participation 30 days prior to enrollment that includes exposure to an investigational drug that would interfere with this study.
* Any disease or condition which would interfere with study participation or unduly increase risk.
* Presence of an electrically sensitive support system such as a pacemaker.
* Known history of epilepsy.
* Presence of metal implants or metal braces on teeth.
25 Years
55 Years
FEMALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Massachusetts General Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Molly A. Wanner, MD
Assistant Physician, Dermatology
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Molly Wanner, MD
Role: PRINCIPAL_INVESTIGATOR
MGH
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Massachusetts General Hospital
Boston, Massachusetts, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2009-P-002803
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.